Recent Progress in Rett Syndrome and MeCP2 Dysfunction: Assessment of Potential Treatment Options

Overview

Journal Future Neurol

Specialty Neurology

Date 2013 Dec 19

PMID 24348096

Citations 16

Authors

Christopher A Chapleau

Jane Lane

Jennifer Larimore

Wei Li

Lucas Pozzo-Miller

Alan K Percy

Affiliations

Soon will be listed here.

Abstract

Synaptic communication is highly regulated process of contact between cells allowing information to be stored and modified. Synaptic formation and maturation is the result of interactions between intrinsic genetic/molecular factors and the external environment to establish the communication in the brain. One disorder associated with faulty synapse communication is Rett Syndrome (RTT). RTT is the leading form of severe MR in females, affecting approximately 1:10,000 females worldwide, without predisposition to any particular racial or ethnic group. Mutations in , the gene encoding methyl-CpG-binding protein-2, have been identified in more than 95% of individuals with RTT. Birth and the milestones of early development appear to be normal in individuals with RTT until approximately 6-18 months when in the subsequent months and years that follows, physical, motor, and social-cognitive development enter a period of regression. The clinical management of these individuals is extremely multifaceted, relying on collaborations of specialists and researchers from many different fields. In this critical literature review, we provide an overview of Rett Syndrome, from patient to pathophysiology with a therapeutic summary of clinical trials in RTT and preclinical studies using mouse and cell models of RTT.

Citing Articles

Delayed Ventricular Repolarization and Sodium Channel Current Modification in a Mouse Model of Rett Syndrome.

Cheng H, Charles I, James A, Abdala A, Hancox J Int J Mol Sci. 2022; 23(10).

PMID: 35628543 PMC: 9147596. DOI: 10.3390/ijms23105735.

Role of DNA Methyl-CpG-Binding Protein MeCP2 in Rett Syndrome Pathobiology and Mechanism of Disease.

Pejhan S, Rastegar M Biomolecules. 2021; 11(1).

PMID: 33429932 PMC: 7827577. DOI: 10.3390/biom11010075.

Identification of hsa-miR-1275 as a Novel Biomarker Targeting for Human Epilepsy of Unknown Etiology.

Zhao Y, Lu C, Wang H, Lin Q, Cai L, Meng F Mol Ther Methods Clin Dev. 2020; 19:398-410.

PMID: 33251277 PMC: 7677659. DOI: 10.1016/j.omtm.2020.10.005.

Epigenetic marks and their relationship with BDNF in the brain of suicide victims.

Misztak P, Panczyszyn-Trzewik P, Nowak G, Sowa-Kucma M PLoS One. 2020; 15(9):e0239335.

PMID: 32970734 PMC: 7513998. DOI: 10.1371/journal.pone.0239335.

Rett Syndrome and CDKL5 Deficiency Disorder: From Bench to Clinic.

Kadam S, Sullivan B, Goyal A, Blue M, Smith-Hicks C Int J Mol Sci. 2019; 20(20).

PMID: 31618813 PMC: 6834180. DOI: 10.3390/ijms20205098.

References

Deng V, Matagne V, Banine F, Frerking M, Ohliger P, Budden S . FXYD1 is an MeCP2 target gene overexpressed in the brains of Rett syndrome patients and Mecp2-null mice. Hum Mol Genet. 2007; 16(6):640-50. DOI: 10.1093/hmg/ddm007. View

Chahrour M, Jung S, Shaw C, Zhou X, Wong S, Qin J . MeCP2, a key contributor to neurological disease, activates and represses transcription. Science. 2008; 320(5880):1224-9. PMC: 2443785. DOI: 10.1126/science.1153252. View

Neul J, Kaufmann W, Glaze D, Christodoulou J, Clarke A, Bahi-Buisson N . Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol. 2010; 68(6):944-50. PMC: 3058521. DOI: 10.1002/ana.22124. View

Cohen S, Gabel H, Hemberg M, Hutchinson A, Sadacca L, Ebert D . Genome-wide activity-dependent MeCP2 phosphorylation regulates nervous system development and function. Neuron. 2011; 72(1):72-85. PMC: 3226708. DOI: 10.1016/j.neuron.2011.08.022. View

Armstrong D, Dunn J, Antalffy B, Trivedi R . Selective dendritic alterations in the cortex of Rett syndrome. J Neuropathol Exp Neurol. 1995; 54(2):195-201. DOI: 10.1097/00005072-199503000-00006. View

Kirby R, Lane J, Childers J, Skinner S, Annese F, Barrish J . Longevity in Rett syndrome: analysis of the North American Database. J Pediatr. 2009; 156(1):135-138.e1. PMC: 2794941. DOI: 10.1016/j.jpeds.2009.07.015. View

Trappe R, Laccone F, Cobilanschi J, Meins M, Huppke P, Hanefeld F . MECP2 mutations in sporadic cases of Rett syndrome are almost exclusively of paternal origin. Am J Hum Genet. 2001; 68(5):1093-101. PMC: 1226090. DOI: 10.1086/320109. View

Tropea D, Giacometti E, Wilson N, Beard C, McCurry C, Fu D . Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice. Proc Natl Acad Sci U S A. 2009; 106(6):2029-34. PMC: 2644158. DOI: 10.1073/pnas.0812394106. View

Amir R, Van den Veyver I, Wan M, Tran C, Francke U, Zoghbi H . Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet. 1999; 23(2):185-8. DOI: 10.1038/13810. View

10.

Brendel C, Belakhov V, Werner H, Wegener E, Gartner J, Nudelman I . Readthrough of nonsense mutations in Rett syndrome: evaluation of novel aminoglycosides and generation of a new mouse model. J Mol Med (Berl). 2010; 89(4):389-98. PMC: 3055984. DOI: 10.1007/s00109-010-0704-4. View

11.

Goffin D, Allen M, Zhang L, Amorim M, Wang I, Reyes A . Rett syndrome mutation MeCP2 T158A disrupts DNA binding, protein stability and ERP responses. Nat Neurosci. 2011; 15(2):274-83. PMC: 3267879. DOI: 10.1038/nn.2997. View

12.

Johnson R, Lam M, Punzo A, Li H, Lin B, Ye K . 7,8-dihydroxyflavone exhibits therapeutic efficacy in a mouse model of Rett syndrome. J Appl Physiol (1985). 2011; 112(5):704-10. PMC: 3643819. DOI: 10.1152/japplphysiol.01361.2011. View

13.

Marchetto M, Carromeu C, Acab A, Yu D, Yeo G, Mu Y . A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell. 2010; 143(4):527-39. PMC: 3003590. DOI: 10.1016/j.cell.2010.10.016. View

14.

Schmid D, Yang T, Ogier M, Adams I, Mirakhur Y, Wang Q . A TrkB small molecule partial agonist rescues TrkB phosphorylation deficits and improves respiratory function in a mouse model of Rett syndrome. J Neurosci. 2012; 32(5):1803-10. PMC: 3710112. DOI: 10.1523/JNEUROSCI.0865-11.2012. View

15.

Belichenko P, Oldfors A, Hagberg B, Dahlstrom A . Rett syndrome: 3-D confocal microscopy of cortical pyramidal dendrites and afferents. Neuroreport. 1994; 5(12):1509-13. View

16.

Popescu A, Sidorova E, Zhang G, Eubanks J . Aminoglycoside-mediated partial suppression of MECP2 nonsense mutations responsible for Rett syndrome in vitro. J Neurosci Res. 2010; 88(11):2316-24. DOI: 10.1002/jnr.22409. View

17.

Ellaway C, Peat J, Williams K, Leonard H, Christodoulou J . Medium-term open label trial of L-carnitine in Rett syndrome. Brain Dev. 2001; 23 Suppl 1:S85-9. DOI: 10.1016/s0387-7604(01)00346-1. View

18.

Quaderi N, Meehan R, Tate P, Cross S, Bird A, Chatterjee A . Genetic and physical mapping of a gene encoding a methyl CpG binding protein, Mecp2, to the mouse X chromosome. Genomics. 1994; 22(3):648-51. DOI: 10.1006/geno.1994.1442. View

19.

DErcole A, Ye P, OKusky J . Mutant mouse models of insulin-like growth factor actions in the central nervous system. Neuropeptides. 2002; 36(2-3):209-20. DOI: 10.1054/npep.2002.0893. View

20.

Amir R, Van den Veyver I, Schultz R, Malicki D, Tran C, Dahle E . Influence of mutation type and X chromosome inactivation on Rett syndrome phenotypes. Ann Neurol. 2000; 47(5):670-9. View